当前位置:
X-MOL 学术
›
Bipolar Disord.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Supercharging collaboration for bipolar research—Breakthrough discoveries for thriving with bipolar disorder (BD2)
Bipolar Disorders ( IF 5.4 ) Pub Date : 2023-12-21 , DOI: 10.1111/bdi.13398 C. M. Altimus 1 , E. G. Baxi 1 , M. A. Frye 2 , E. J. Nestler 3 , D. L. Pham 1 , K. E. Burdick 4
中文翻译:
加强双相情感障碍研究的合作——突破性发现促进双相情感障碍 (BD2) 的蓬勃发展
更新日期:2023-12-22
Bipolar Disorders ( IF 5.4 ) Pub Date : 2023-12-21 , DOI: 10.1111/bdi.13398 C. M. Altimus 1 , E. G. Baxi 1 , M. A. Frye 2 , E. J. Nestler 3 , D. L. Pham 1 , K. E. Burdick 4
Affiliation
CONFLICT OF INTEREST STATEMENT
CMA, EGB, EJN, and DLP have nothing to disclose. MAF receives grant support from Assurex Health; honoraria from Carnot Laboratories and American Physician Institute; and has a financial interest in Chymia LLC. KEB receives honoraria from Merck.
中文翻译:
加强双相情感障碍研究的合作——突破性发现促进双相情感障碍 (BD2) 的蓬勃发展
利益冲突声明
CMA、EGB、EJN 和 DLP 没有任何可披露的信息。MAF 获得 Assurex Health 的拨款支持;卡诺实验室和美国医师协会的酬金;并拥有 Chymia LLC 的经济利益。KEB 收到默克公司的酬金。